ArticleFrontiers in medicine2022
Progression-Free Survival Prediction in Small Cell Lung Cancer Based on Radiomics Analysis of Contrast-Enhanced CT.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Baseline ¹BMC cancer · 2026Article
- Contrast-enhanced computed tomography-based intratumoral and peritumoral radiomics for identifying malignancy in pulmonary ground-glass nodules.Journal of thoracic disease · 2025Article
- Pilot Exploratory Study of a CT Radiomics Model for the Classification of Small Cell Lung Cancer and Non-Small-Cell Lung Cancer in the Moscow Population: A Step Toward Virtual Biopsy.Journal of imaging · 2025Article
- FLAIR-based radiomics signature from brain-tumor interface for early prediction of response to EGFR-TKI therapy in NSCLC patients with brain metastasis.Frontiers in cell and developmental biology · 2025Article
- Predicting response and survival to first-line treatment with baseline [Therapeutic advances in medical oncology · 2025Article
- Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer.BJR open · 2025Review
- Dual-Phase Enhanced CT-Derived Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV Lung Adenocarcinoma.Cancer medicine · 2024Article
- Risk stratification and overall survival prediction in extensive stage small cell lung cancer after chemotherapy with immunotherapy based on CT radiomics.Scientific reports · 2024Article
- Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer.Thoracic cancer · 2024Article
- Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer.BMC cancer · 2024Article
- Predicting the pathological invasiveness in patients with a solitary pulmonary nodule via Shapley additive explanations interpretation of a tree-based machine learning radiomics model: a multicenter study.Quantitative imaging in medicine and surgery · 2023Article
- A CT-based radiomics nomogram for predicting the progression-free survival in small cell lung cancer: a multicenter cohort study.La Radiologia medica · 2023Article
- Article
- A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study.Clinical and translational science · 2022Article
- Peritumoral Radiomic Features on CT for Differential Diagnosis in Small-Cell Lung Cancer: Potential for Surgical Decision-Making.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purposes and Objectives: The aim of this study was to predict the progression-free survival (PFS) in patients with small cell lung cancer (SCLC) by radiomic signature from the contrast-enhanced computed tomography (CT). Methods: A total of 186 cases with pathological confirmed small cell lung cancer were retrospectively assembled. First, 1,218 radiomic features were automatically extracted from tumor region of interests (ROIs) on the lung window and mediastinal window, respectively. Then, the prognostic and robust features were selected by machine learning methods, such as (1) univariate analysis based on a Cox proportional hazard (CPH) model, (2) redundancy removing using the variance inflation factor (VIF), and (3) multivariate importance analysis based on random survival forests (RSF). Finally, PFS predictive models were established based on RSF, and their performances were evaluated using the concordance index (C-index) and the cumulative/dynamic area under the curve (C/D AUC). Results: In total, 11 radiomic features (6 for mediastinal window and 5 for lung window) were finally selected, and the predictive model constructed from them achieved a C-index of 0.7531 and a mean C/D AUC of 0.8487 on the independent test set, better than the predictions by single clinical features (C-index = 0.6026, mean C/D AUC = 0.6312), and single radiomic features computed in lung window (C-index = 0.6951, mean C/D AUC = 0.7836) or mediastinal window (C-index = 0.7192, mean C/D AUC = 0.7964). Conclusion: The radiomic features computed from tumor ROIs on both lung window and mediastinal window can predict the PFS for patients with SCLC by a high accuracy, which could be used as a useful tool to support the personalized clinical decision for the diagnosis and patient management of patients with SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.